Lupin receives USFDA approval for Generic Prilosec Capsules

27 Aug 2015 Evaluate

Lupin has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP (AstraZeneca) Prilosec Delayed-Release capsules 40 mg. Lupin's Omeprazole Delayed-Release capsules 40 mg are the AB rated generic equivalent of AstraZeneca's Prilosec Delayed-Release capsules 40mg.

It is indicated for the short-term treatment of Duodenal Ulcer, Gastric Ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of Erosive Esophagitis and Pathological Hypersecretory conditions.  Prilosec had annual US sales of $185 million (IMS MAT June 2015).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

Lupin Share Price

2103.25 -0.05 (0.00%)
02-Jan-2026 09:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.15
Dr. Reddys Lab 1240.70
Cipla 1504.95
Zydus Lifesciences 914.65
Lupin 2103.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×